Authors
Latest:
Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETsFinal overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.
Latest:
Challenges Hinder Machine Learning's Potential in OncologyJames Zou, PhD, elaborates on some of the challenges associated with machine learning techniques and its utilization in oncology.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Real-World Data on Brexu-cel in Relapsed/Refractory B-Cell ALLIn an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.
Latest:
Detecting and Addressing Hard-to-Find Skin CancersNiraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Darolutamide/ADT Safe, Effective for Black Men with Metastatic Prostate CancerAn ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.
Latest:
Future Research Aims to Examine Blocking STAT3 in Acute Myeloid LeukemiaMarcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.
Latest:
Individulizing Treatment and Exploring Options in Ovarian CancerChristina Fotopoulou, MD, PhD, discusses recent developments in ovarian cancer and explains how one can individualize treatments when managing patients.
Latest:
How Data Help Physicians Improve Operations and Achieve Health EquityA US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Latest:
Glioblastoma Treatment Is Slow to Change, but New Strategies Are Under InvestigationDuring the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.
Latest:
Final ThoughtsPanelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.
Latest:
Steady Progress of AI Makes its Mark in the ClinicIncreasingly, and with exponential pace, AI algorithms are finding their way into the oncology clinic.
Latest:
Key Takeaways from SABCS 2023 in HER2+ Breast CancerFollowing their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
Latest:
Next Steps to Further Understand Uterine SarcomaMatthew A. Ingham, MD, discusses the key takeaways from an article he co-authored regarding novel therapeutics in uterine sarcoma.
Latest:
Treatment Implementation and Long-Term Considerations in BPDCNPanelists discuss how optimizing shared-care models between academic and community centers enhances continuity in complex hematologic malignancies. Key monitoring parameters for tagraxofusp include capillary leak syndrome risk. Timely transplant referral depends on disease kinetics. Novel therapies are among the unmet needs in plasmacytoid dendritic cell neoplasm. Support resources aid patient management. Emerging treatments and clinical insights continue to advance care.
Latest:
Improving Prostate Cancer Screening With an AI ModelMadhur Nayan, MD, PhD, discusses a new machine learning model developed to enhance prostate cancer screening.
Latest:
Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating AgentsExperts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.
Latest:
Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer TherapiesDuring a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.
Latest:
Keeping Track of FGFR Inhibitor AEs Leads to Optimal OutcomesThis article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.
Latest:
Ladbury Discusses Advancements in Total Marrow IrradiationColton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual Meeting.
Latest:
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCLMichael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.
Latest:
Caring for Patients With Cancer as COVID Rates Continue to RiseStringent and dedicated interventions are necessary to handle the spread of COVID-19, as this represents a major healthcare challenge for humanity, says Daniel Vorobiof, MD.
Latest:
Statins: Unexpected Allies in Cancer? Promising New Research in CLLAhmad Abuhelwa, MD, discusses the significance of a study exploring statin use in patients with chronic lymphocytic leukemia.
Latest:
Discussing Treatment Options and Recent Trials in the Thyroid Cancer SpaceMelanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab VedotinJohn Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.
Latest:
Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast CancerEcaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
